Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04648254 · ClinicalTrials.gov registry record · Phase 1
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor
A Phase 1 study, sponsored by Qurient Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT04648254 is a Phase 1 study that has completed, run by Qurient Co.. The registered enrollment target is 51 participants.
The verdict
NCT04648254, a Phase 1 study, has completed, sponsored by Qurient Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, multicenter, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic study with cohort expansion at the RP2D to evaluate safety and anti- tumor activity of Q702 administered orally.
Interventions
- DRUG Q702
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2020-11-18 |
| Est. Completion | 2025-12-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04648254
The ClinicalTrials.gov registry entry for NCT04648254 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Qurient Co., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Q702 is the first listed.
NCT04648254 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04648254 about?
NCT04648254 is a clinical study titled "Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor". This is a Phase 1, open-label, multicenter, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic study with cohort expansion at the RP2D to evaluate safety and anti- tumor activity of Q702 administered orally.
What is the current status of trial NCT04648254?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2020-11-18. Estimated completion is 2025-12-23.
What interventions are being tested in trial NCT04648254?
The interventions under investigation include: Q702 (DRUG).
Who is sponsoring clinical trial NCT04648254?
This trial is sponsored by Qurient Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.